Logo Image
|Articles|January 11, 2023

Pharmaceutical Executive

  • Pharmaceutical Executive: January 2023
  • Volume 43
  • Issue 01

What We Foresee in ’23: Pharm Exec’s Annual Industry Outlook

Exploring the most relevant topics affecting the biopharma industry as the new year gets underway—ranging from trends ripe with risk and opportunity to those driving more definitive growth opportunities in patient care.

Our 2023 trends:

Cybersecurity

Pharma Workforce

Social Media

Patient Hubs

Inflation Reduction Act

Partnering with Academia

Articles in this issue

over 3 years ago

Key Factors Attributing to a Successful Product Launch

over 3 years ago

Closing the Digital Gap: FDA’s Oversight of Social Media

over 3 years ago

Sales-Rep Compensation: Adding Long-Term Incentives to Mix

over 3 years ago

Stars Aligned for Pricing Model? Value-Based Contracts May be Poised for Takeoff

over 3 years ago

Co-creating New Innovations

over 3 years ago

The Potential Impact of the IRA

over 3 years ago

Patient Hubs Continue Growth

over 3 years ago

Social Media’s Complex Climb

over 3 years ago

Industry Workforce Seeks Clarity

over 3 years ago

Cybersecurity Threats & Pharma

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more